Halberd Corp (HALB)

[EHRjunkie]

Patience. HALB was successful in developing at ASU a new generation of monoclonal antibodies against Covid19. HALB is now in the proces of building products around their (provisional) patented antibodies. So next phase will be attracting JV-partners to bring their rapid test and nasal spray to market. That should bring in a revenue stream and with the funding they have in place already they should be able to go for their ultimate goal, the development and clinical testing of the extracorporeal treatment that is fully patented.
We were able to follow their work on the antibodies. Soon we should get press releases about JV partners and manufacturers. And in 2 weeks HALB has to file the financials Q1 2021 showing that $2 million funding through ESC in Louisiana. If you don't have faith in HALB's management there's no reason to be shareholder, but if you do you're long and wait. And I've said it before, I'm all in. Good luck.